frontiers in Immunology

CORRECTION
published: 06 December 2021
doi: 10.3389/fimmu.2021.808068

Corrigendum: Humanized Mice for the Evaluation of Novel HIV-1 Therapies

Shawn Abeynaike[1,2] *and Silke Paust*[1,2]*

[1] Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States, [2] The Skaggs Graduate Program in Chemical and Biological Sciences, The Scripps Research Institute, La Jolla, CA, United States

OPEN ACCESS

Edited and reviewed by:
Qingfeng Chen,
Institute of Molecular and Cell Biology (A*STAR), Singapore

***Correspondence:**
Silke Paust
paust@scripps.edu

Specialty section:
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology

Received: 03 November 2021
Accepted: 08 November 2021
Published: 06 December 2021

Citation:
Abeynaike S and Paust S (2021) Corrigendum: Humanized Mice for the Evaluation of Novel HIV-1 Therapies. Front. Immunol. 12:808068. doi: 10.3389/fimmu.2021.808068

Keywords: humanized mice, BLT, DRAG, HIV-1 infection, viral latency, latency reversal, immunotherapy, gene therapy

A Corrigendum on:

Humanized Mice for the Evaluation of Novel HIV-1 Therapies
By Abeynaike S and Paust S (2021). Front. Immunol. 12:636775. doi: 10.3389/fimmu.2021.636775

In the original article, there was a mistake in **Table 1** as published. The authors incorrectly categorized thy/liv implanted SCID-hu mice as showing no multilineage hematopoeisis. To clarify, Namikawa 1990, showed that SCID mice implanted with both Thy/Liv displayed multilineage hematopoiesis. Specifically, they showed in addition to T cells (CD3, CD4 and CD8), the presence of mature and immature forms of myelomonocytic cells which stained positive for human CD15, as well as progenitors for erythroids and megakaryocytic lineages (1).

The corrected **Table 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 | Summary of humanized mouse models and their tissue-based chimerism.

	SCID-hu	hu-PBL	hu-HSC	BLT	TKO-BLT
Mouse Model					
Genetic Background	C.B17scid/scid (SCID)	SCID NOD-SCID NSG BRG NCG	SCID NOD-SCID NSG BRG NRG DRAG	SCID NOD-SCID NSG NRG	C57BL/6 Rag2 $^{-/-}$ $g_c^{-/-}$
Humanization Method	Subcapsular Coimplantation of human fetal thymus and liver fragments 	Intraperitoneal Injection of human PBMCs 	Injection of CD34+ cells from cord blood/fetal liver 	Coimplantation human fetal thy/liv with i.v. injection of CD34+ cells from fetal liver 	Coimplantation human fetal thy/liv with i.v. injection of CD34+ cells from fetal liver 
Immune Reconstitution	T cell engraftment Multilineage hematopoiesis No primary immune response	T cell engraftment No multilineage hematopoiesis No primary immune response	Multilineage hematopoiesis Primary immune response No HLA restriction	Multilineage hematopoiesis Primary immune response Human HLA T cell restriction	Multilineage hematopoiesis Primary immune response Human HLA T cell restriction
References	McCune Namikawa (11), Namikawa Weilbaecher (12)	Moiser, Gulizia (13), Hesselton. Greiner (14), van Rijn, Simonetti (15), Ali, Flutter (16)	Kamei-Reid and Dick (17), Peault, Weissman (18), Hiramatsu, Nishikomori (19), Danner, Chaudhari (20)	Lan, Tonomura (21), Melkus, Estes (22), Brainard, Seung (23), Stoddart, Maidji (24)	Lavender, Messer (25), Lavender, Pang (26), Lavander, Pace (27)

Created with BioRender.com.

REFERENCE

1. Namikawa R, Weilbaecher K, Kaneshima H, Yee E, Mccune J. Long-Term Human Hematopoiesis in the SCID-hu Mouse. *J Exp Med* (1990) 172 (4):1055–63.